Lineage Cell CFO granted 1.05M stock options

Lineage Cell Therapeutics, Inc. reported that Chief Financial Officer Jill Ann Howe received a grant of 1,050,000 employee stock options on March 5, 2026.

Rhea-AI Filing Summary

Lineage Cell Therapeutics, Inc. reported that Chief Financial Officer Jill Ann Howe received a grant of 1,050,000 employee stock options on March 5, 2026. These options carry a stated exercise price of $0.0000 per share, reflecting a compensatory award rather than an open-market purchase.

According to the terms, one quarter of the options will vest on March 5, 2027. The remaining three quarters will then vest in 36 equal monthly installments, contingent on the completion of each month of continuous employment. Following this grant, Howe’s directly held option position from this award totals 1,050,000 options.

Insider Trade Summary

Grant/Award: 1,050,000 shares

Grant/Award 1 txn

Insider Howe Jill Ann

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	1,050,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 1,050,000 contracts (Direct)

Footnotes (1)

1. F1. One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lineage Cell Therapeutics (LCTX) report for Jill Ann Howe?

Lineage Cell Therapeutics reported that Chief Financial Officer Jill Ann Howe received a grant of 1,050,000 employee stock options. The award was recorded as an acquisition under a grant or award code, not as an open-market purchase or sale of existing common shares.

How many stock options were granted to the Lineage Cell (LCTX) CFO in this Form 4?

The Form 4 shows a grant of 1,050,000 employee stock options to Chief Financial Officer Jill Ann Howe. After this transaction, her holdings from this award total 1,050,000 derivative securities, reflecting a new compensatory option position rather than a cash purchase on the market.

What is the vesting schedule for Jill Ann Howe’s 1,050,000 Lineage Cell (LCTX) stock options?

One quarter of the 1,050,000 options will vest on March 5, 2027. The remaining three quarters will vest in 36 monthly installments, each tied to completing a month of continuous employment, creating a multi‑year, service-based vesting structure for the award.

Was the Lineage Cell (LCTX) CFO’s Form 4 transaction a stock purchase or an option grant?

The Form 4 reflects an option grant, not a stock purchase or sale. It is coded as a grant, award, or other acquisition of derivative securities, specifically employee stock options, with no reported open-market transaction price per share for existing common stock.

How is ownership characterized for the Lineage Cell (LCTX) CFO’s new option grant?

The filing characterizes the 1,050,000 employee stock options as held with direct ownership by Jill Ann Howe. The direct ownership code indicates the options are attributed personally to her, without reference to any intermediary entities such as trusts, LLCs, or family partnerships.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/06/2026 - 07:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Howe Jill Ann

(Last) (First) (Middle)

C/O LINEAGE CELL THERAPEUTICS

2173 SALK AVENUE, SUITE 200

(Street)

CARLSBAD CA 92008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lineage Cell Therapeutics, Inc. [ LCTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$1.84	03/05/2026		A		1,050,000		(1)	03/05/2036	Common Shares	1,050,000	$0	1,050,000	D

Explanation of Responses:

1. One quarter of the options shall vest on March 5, 2027, and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.

	/s/ Jill A. Howe	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.